Evaluation of the physicochemical properties of liposomes as potential carriers of anticancer drugs: spectroscopic study
- 262 Downloads
Vesicle size and composition are a critical parameter for determining the circulation half-life of liposomes. Size influences the degree of drug encapsulation in liposomes. The geometry, size, and properties of liposomes in an aqueous environment have to be described to enable potential applications of liposome systems as drug carriers. The characteristics of multiple thermotropic phase transitions are also an important consideration in liposomes used for analytical and bioanalytical purposes. The aim of this study was to evaluate the physicochemical properties of liposomes which accommodate hydrophilic and amphiphilic drugs used in cancer therapy. The studied liposomes were prepared with the involvement of the modified reverse-phase evaporation method (mREV). The prepared liposomes had a diameter of 70–150 nm. The analyzed compounds were 1-β-d-arabinofuranosylcytosine, cyclophosphamide, and ifosfamide. In literature, there is no information about simultaneous incorporation of cytarabine, ifosfamide, and cyclophosphamide, in spite of the fact that these drugs have been used for more than 30 years. A combination of the examined drugs is used in CODOX-M/IVAC therapy. CODOX-M/IVAC (cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine) is one of the currently preferred intensive-dose chemotherapy regimens for Burkitt lymphoma (BL). The present research demonstrates the pioneering studies of incorporation of ifosfamide into liposome vesicles, location of and competition between the analyzed drugs and liposome vesicles. The applied methods were nuclear magnetic resonance (NMR), atomic force microscopy (AFM), differential scanning calorimetry (DSC).
KeywordsNanomedicine Drug delivery Liposome mREV NMR AFM DSC
This study was supported by the State Committee for Scientific Research in Poland (N N204 139039).
- Gaynor ER, Ultmann JE, Golomb HM, Sweet DL (1985) Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol 3:1596–1604Google Scholar
- Guglielmi C, Amadori S, Martelli M (1992) F-MACHOP in advanced aggressive lymphoma. Leuk Lymphoma 7:205–209Google Scholar
- Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Norbert P, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma:results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274CrossRefGoogle Scholar
- Parker BA, Santarelli M (1993) AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a cancer and leukemia Group B study. J Clin Oncol 11:248–254Google Scholar
- Smith HJ, Smith JR, Multi-drug liposomes to treat tumors, Patent Application Publication, Pub. No.: US 2012/0231066 A1, United StatesGoogle Scholar
- Zhong Q, Inniss D, Kjoller K, Elings VB (1993) Fractured polymer/silica fiber surface studied by tapping mode atomic force microscopy. Surf Sci Lett 290:688–692Google Scholar